Harrow News

KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday.Shares of KB Home (NYSE:KBH) rose during Thursday's session as the company posted better-than-expected earnings a

BenzingaJun 20 10:21 ET

Harrow Rises 15% In Pre-market

RTTNewsJun 20 08:49 ET

Market-Moving News for June 20th

HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also th

BenzingaJun 20 08:17 ET

Express News | Harrow Shares Are Trading Higher After the Company Announced the Manufacture of the First of Three Commercial-scale Process Performance Qualification Batches of TRIESENCE 40 Mg/mL. Also the Company Announced That the Second and Third Required PPQ...

BenzingaJun 20 08:11 ET

Harrow Hopes To Relaunch Triesence This Year

RTTNewsJun 20 07:54 ET

Harrow Announce Manufacture Of First Of Three Commercial-Scale Process Performance Qualification Batches Of Triesence For Visualization During Vitrectomy And Ocular Inflammatory Conditions, Harrow Says Second & Third Required PPQ Batches Are Scheduled

Harrow Announce Manufacture Of First Of Three Commercial-Scale Process Performance Qualification Batches Of Triesence For Visualization During Vitrectomy And Ocular Inflammatory Conditions, Harrow Say

BenzingaJun 20 07:27 ET

Express News | Harrow: IF Ppq Batches Meet Specifications, New Triesence Production Process to Be Deemed Complete, Allowing Co to Relaunch During 2024

ReutersJun 20 07:10 ET

Express News | Harrow Inc: Successful Manufacture of Triesence Ppq Batch

ReutersJun 20 07:09 ET

Express News | Harrow Provides Triesence® Relaunch Update

ReutersJun 20 07:00 ET

B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29

B.Riley Financial analyst Mayank Mamtani maintains $Harrow(HROW.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 25.4% and a

moomoo NewsJun 6 14:32 ET

Express News | Corrected-Melt Pharmaceuticals (Not 'harrow Inc'): Topline Readout Expected in Q4 2024

ReutersJun 6 08:48 ET

Express News | Harrow Inc: Topline Readout Expected in Q4 2024

ReutersJun 6 08:00 ET

Express News | Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

ReutersJun 6 08:00 ET

Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating

Craig-Hallum analyst Chase Knickerbocker maintains $Harrow(HROW.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 2.7% over the p

moomoo NewsJun 5 09:33 ET

Harrow's VEVYE Shows Results for Dry Eye Disease in ESSENCE-2 Study

Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‐2 open-label extension (OLE) clinical study for VEVYE (cyclosporine ophth

BenzingaJun 5 07:10 ET

Express News | Harrow Announces 52-Week Data From Vevye® Essence-2 Open-Label Extension Study

ReutersJun 5 07:00 ET

Harrow Is Maintained at Buy by Lake Street

Harrow Is Maintained at Buy by Lake Street

Dow JonesJun 3 11:11 ET

Express News | Lake Street Maintains Buy on Harrow, Raises Price Target to $25

BenzingaJun 3 11:01 ET

The AISL Harrow Scholarships 2024/26: Doubling Success, as Awardees Soar to New Heights

Yahoo FinanceMay 27 02:00 ET

Harrow (NASDAQ:HROW) Stock Surges on Successful Product Launch

TipRanksMay 23 06:29 ET